KIT and melanoma: KIT inhibitors, like Imatinib, has been applied clinically in melanoma patients for years, but we still need to explore more drugs targeting c-KIT and other biomarkers, due to the phenotypic plasticity that there are many molecular subtypes and variations in melanoma 2.